Drug Profile

STRX 240

Alternative Names: AAV-based Dravet syndrome therapy - Sarepta Therapeutics/StrideBio; STRX-240

Latest Information Update: 28 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator StrideBio
Class Antiepileptic drugs; Gene therapies
Mechanism of Action Gene transference; NAV1.1 voltage-gated sodium channel expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Dec 2023 No recent reports of development identified for research development in Dravet-syndrome in USA (Parenteral)
14 Nov 2019 StrideBio and Sarepta Therapeutics agree to co-develop Dravet syndrome gene therapies
14 Nov 2019 Early research in Dravet syndrome in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com